To review current literature of the benefits that aspirin
provides for patients' cardiovascular
health compared with the risk of AMD worsening.
We performed a review and critically analyzed six cardiovascular
and four ophthalmological trials regarding risks and benefits of aspirin
use. The prospective randomized cardiovascular
trials had a cumulative 167,580 while the 3 smaller ophthalmological data sets had a cumulative 12,015 subjects.
The reviewed meta-analysis literature demonstrated a statistically significant 32% reduction in the risk of nonfatal stroke
with regular aspirin
users. The study also documented that aspirin
users decreased the risk of fatal vascular
deaths by 15%. Of the three ophthalmological studies highlighting the adverse affects of aspirin
association with AMD, all suggested an exacerbation of AMD without statistical significance and broad confidence bands.
Overall, the number, size, and quality of the cardiovascular
studies recommending aspirin
use are far superior to the fewer, smaller and conflicting studies suggesting a possible adverse effect of aspirin
use in relation to AMD. The benefits of aspirin
usage include preserving the duration and quality of life by decreasing stroke
and heart attack risk. These benefits seem to far outweigh the theoretical risks of possibly exacerbating wet AMD
, which can be reasonably controlled with anti-VEGF therapy.